bigdaddyandfriends
Member
That's smart. And the biochemistry of supports it.
EQ, primo, and DHB are all boldenone derivatives. Here is the missing branch of the steroid family tree:
Testosterone + C1-2 double bond > Boldenone (Parenabol)
Boldenone w/ C17 undecylenate ester > EQ (Equipoise)
Boldenone w/ C17 methylation > metendienone (Dianabol)
Boldenone + synthetic 5⍺-reduction w/ cypionate ester > DHB
DHB + c1-methylation w/ enanthate ester > primobolan (Nibal)
DHB + c2-methylation w/ acetate ester > stenbolone (Anatrofin)
Note: Dbol because it has no ester and converts to a highly potent synthetic estrogen (7⍺-methylestradiol) has a different effect than the others.
Primo is by far the weakest of the entire group. If primo provides E2 control, so should EQ as that feature comes from the C1-2 double bond; in some people based on their genetics, androgen ligands with it can jam up the aromatase binding site and act as a competitive inhibitor. C1 methylation of primobolan was designed for oral bioavailability of primbolan acetate (same with DHT, where the C1 methylation gives Proviron). Subsequently primobolan depot was created as a oil-soluble injectable by adding a C17-enanthate ester. The C1-methylation may coincidentally offer partial resistance to 3⍺-HSD in skeletal muscle, but primobolan's main metabolites are 3⍺-hydroxylated, so not that much - it is not particularly anabolic, certainly less so than testosterone and all the others listed above, and probably little more than Proviron. Basically it's a very expensive AI - and inferior in that regard to aromasin, another synthetic androgen that permanently disable aromatase in essentially everyone, making ratios with aromatizing androgens mostly irrelevant. The only real problem with aromasin is the available dosing - it should be offered for men in 3.125mg or 6.25mg tabs, not 25mg which is the post-menopausal female breast cancer dose designed to eliminate estrogen production, although in practice that is less likely to happen in men. I've been buying Exesin (Indian pharma) and breaking it up into quarters, not easy as they are very tiny tablets. Solutions are a better option, but not available as pharma and dosing of UGL/research AIs is inherently suspect.
If you want to use an injectable for estrogen control, EQ is much cheaper/available, more anabolic and should be at least as effective as primobolan. And the hematocrit raising effects of EQ and primobolan are quite similar, although EQ primarily has the bad rep for it probably because it is typically dosed quite high. Primobolan also has significant PIP potential, EQ does not and injection volumes are much lower with EQ which typically comes in 2-3x the concentration with < 25% the price per ml.
Methylation and other alterations at C2, rather than C1, are specifically designed to resist degradation by 3⍺-HSD, so increase anabolism in muscle. Drostanolone/Masteron (DHT based) and stenbolone/Anatrofin (DHB based) are in this category; so are ALL the other so-called "DHT derivatives" with high anabolic:androgenic ratios (except primobolan) - ie oxandrolone, oxymetholone, and stanzolol which has a unique C2-3 ring modification. C-C2-C3 is target on the A-ring to manipulate the parent hormone's resistance to 3⍺-HSD.
